Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Mazdutide

MARKETED

GLP-1 and glucagon receptor dual agonist

10
graded results
2
ongoing records
8
effect domains
Evidence spread
High evidence 0Moderate evidence 5Low evidence 3Very low evidence 2

Mazdutide has a current marketed status in the scoped regulatory record below. Results describe observations and do not provide treatment advice.

Dated status sources

MARKETED China; Chronic weight management; Subcutaneous injection; as of 2026-07-13. Innovent reporting NMPA approval

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Mazdutide MARKETED
weight-loss Decrease
Moderate evidence

In the registrational Chinese phase-3, the GLP-1/glucagon dual agonist mazdutide produced 11-14% weight loss with low (~1%) discontinuation.

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source
PopulationGLORY-1 (NCT05607680): 610 Chinese adults with obesity or overweight (BMI >=28, or 24-<28 plus a weight-related condition), mazdutide 4/6 mg vs placebo 1:1:1; 48-week phase-3 randomised double-blind placebo-controlled RCT.
FundingInnovent Biologics
Mazdutide MARKETED
weight-loss Decrease
Moderate evidence

Phase 3 GLORY-1 confirmed substantial weight loss vs placebo at 48 wk

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source
PopulationChinese overweight/obese with ≥1 comorbidity (n=610), phase 3, 48 wk, RCT (4/6 mg vs placebo); NEJM 10.1056/NEJMoa2411528
FundingInnovent Biologics
Comparatorsplacebo
Mazdutide MARKETED
weight-loss Decrease
Low evidence

High-dose mazdutide produced marked early weight loss vs placebo in Chinese overweight/obese adults

Ji L et al. EClinicalMedicine 2022;54:101691 Source
PopulationChinese overweight/obese adults (n=24), phase 1b MAD, 12-16 wk, RCT placebo-controlled (NCT04440345)
Fundingindustry - Innovent / Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Mazdutide MARKETED
body-composition Decrease
Very low evidence

GLORY-1/GLORY-2 phase 3 (Chinese adults with obesity): mazdutide met key secondary endpoints including reduced waist circumference and liver-fat content; dual...

Innovent / Eli Lilly, GLORY-1 and GLORY-2 phase 3 (mazdutide) Source
Full findingGLORY-1/GLORY-2 phase 3 (Chinese adults with obesity): mazdutide met key secondary endpoints including reduced waist circumference and liver-fat content; dual GCG/GLP-1 mechanism described as potentially yielding more favourable fat-vs-muscle partition, but no quantified DXA fat/lean split located.
PopulationGLORY-1 (n=610) and GLORY-2 phase 3 RCTs in Chinese adults with obesity; 48-60 weeks
Fundingindustry - Innovent / Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Mazdutide MARKETED
Liver and MASH Not directional
Very low evidence

Mazdutide (IBI362; Innovent/Lilly, GLP-1/glucagon dual) has NO published dedicated human MASH histology trial. Human liver benefit is so far described within...

Gan L, Duan L, Zheng X. Mazdutide ameliorates MASLD (rodent). Pharmaceuticals 2026;19(3):... Source
Full findingMazdutide (IBI362; Innovent/Lilly, GLP-1/glucagon dual) has NO published dedicated human MASH histology trial. Human liver benefit is so far described within obesity/T2D programmes; the histology evidence is rodent. A dedicated clinical MASLD/MASH programme is referenced in reviews but not yet published.
PopulationPreclinical: high-fat-diet mouse MASLD + FFA hepatocytes (PMID 41901218; rodent MRI PMID 40828048). Human MASH histology trial: not yet published.
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Comparatorssemaglutide (preclinical comparator)
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Mazdutide MARKETED
blood-pressure Decrease
Moderate evidence

Mazdutide reduced systolic blood pressure vs placebo (GLORY-1)

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source
PopulationChinese overweight/obese (n=610), phase 3 GLORY-1, 48 wk
FundingInnovent Biologics
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Mazdutide MARKETED
energy-expenditure-thermogenesis Increase
Low evidence

Glucagon-receptor arm proposed to increase energy expenditure and improve hepatic fat metabolism (mammalian OXM analogue)

Sidrak WR et al. Indian J Endocrinol Metab 2024;28:445-460 Source
PopulationMechanistic / review framing
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Comparatorsdulaglutide (preclinical)
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Mazdutide MARKETED
glycaemic Decrease
Moderate evidence

In a phase 3 trial in Chinese adults with T2D, both mazdutide doses were non-inferior and superior to dulaglutide 1.5 mg for HbA1c reduction at 28 weeks (head-to-head).

Guo L et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. Nature ... Source
Population731 Chinese adults with T2D on background oral antidiabetics, randomised 1:1:1; 28-week phase 3 RCT
Fundingindustry - Innovent Biologics (mazdutide licensed from Eli Lilly in China)
Comparatorsdulaglutide 1.5 mg
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Mazdutide MARKETED
lipids-lipoprotein Decrease
Moderate evidence

Reduced total cholesterol, triglycerides, LDL-C and serum uric acid

Mazdutide in Chinese adults with obesity (GLORY-1), NEJM 2025 Source
PopulationChinese overweight/obese (n=610), phase 3, 48 wk
FundingInnovent Biologics
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Mazdutide MARKETED
Stomach and gut Increase
Low evidence

Mild-to-moderate GI TEAEs; no serious AEs in phase 1b

Ji L et al. EClinicalMedicine 2022;54:101691 Source
PopulationChinese overweight/obese (n=24), phase 1b
Fundingindustry - Innovent / Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorsplacebo

Registered or protocol records without results

These records remain discoverable, but they are not counted or presented as results.

Mazdutide MARKETED
weight-loss Decrease REGISTERED, NO RESULTS
Very low evidence

Mazdutide (IBI362 / LY3305677; Innovent, licensed from Lilly) is a GLP-1/glucagon dual agonist (mammalian oxyntomodulin analogue) developed largely in Chinese...

Ji et al., GLORY-1 phase 3, NEJM 2025 (Innovent); ADA 2024; Nat Commun 2023 phase 2 Source
Full findingMazdutide (IBI362 / LY3305677; Innovent, licensed from Lilly) is a GLP-1/glucagon dual agonist (mammalian oxyntomodulin analogue) developed largely in Chinese populations. In phase 3 GLORY-1 (overweight/obesity, no T2D), mean weight change at 48 weeks was -11.00% (4 mg) and -14.01% (6 mg) vs +0.30% placebo (primary endpoint week 32: -10.09% / -12.55% vs +0.45% placebo); 49.5% of the 6 mg group achieved >=15% weight loss vs 2.0% placebo. Phase 2 with a 9 mg dose showed ~20% weight loss at ~48 weeks.
PopulationGLORY-1: 610 Chinese adults overweight (BMI>=24 + comorbidity) or obesity (BMI>=28), once-weekly s.c. 4/6 mg vs placebo, 48 wk; phase 2 (n~248) doses to 9 mg
Fundingindustry - Innovent / Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Mazdutide MARKETED
glycaemic Not directional REGISTERED, NO RESULTS
Very low evidence

DREAMS-3, the first head-to-head mazdutide-vs-semaglutide trial in Chinese adults with T2D + obesity, is designed but results pending (registry/protocol only).

Luo Y et al. Mazdutide versus Semaglutide for T2D and obesity: rationale, design and base... Source
Population349 Chinese adults with T2D (≤10 y) and obesity (BMI ≥28); 32-week open-label active-controlled phase 3 RCT; comparator semaglutide 1 mg
Fundingindustry - Innovent / Eli Lilly (trial sponsor; inferred from registration trial)
Comparatorssemaglutide 1 mg